10
Participants
Start Date
May 8, 2017
Primary Completion Date
July 30, 2018
Study Completion Date
July 30, 2018
plitidepsin
Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
Bortezomib
BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
Dexamethasone
DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
Complexo Hospitalario Universitario de Santiago, Santiago de Compostela
Institut Català d´Oncologia Girona, Girona
Hospital General Universitario J.M. Morales Meseguer, Murcia
Clinica Universidad de Navarra, Pamplona
Hospital Universitario de Salamanca, Salamanca
Complejo Hospitalario Regional Virgen Del Rocio, Seville
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
CHRU de Lille - Hôpital Claude Huriez, Lille
Institut Gustave Roussy, Villejuif
Policlinico Vittorio Emanuele Hospital, Catania
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino
Hospital Universitario Germans Trias i Pujol, Badalona
Institut Català d´Oncologia L´Hospitalet, L'Hospitalet de Llobregat
Lead Sponsor
PharmaMar
INDUSTRY